Akèy › Kansè Vezik ki pa envazif miskilè › Pennsylvania › Lancaster
Etid klinik pou Kansè Vezik ki pa envazif miskilè nan Lancaster, PA
3 etid pou Kansè Vezik ki pa envazif miskilè ap chèche patisipan nan sit nan ak bò kote Lancaster (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer
Ap rekriteFaz 2
- Keystone Urology Specialists, Lancaster
A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
Ap rekriteFaz 3
- Keystone Urology Specialists, Lancaster
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
Ap rekriteFaz 1
- Penn Medicine Lancaster General Hospital - Ann B. Barshinger Cancer Institute, Lancaster
Etid Kansè Vezik ki pa envazif miskilè nan lòt vil
- Columbus, OH10 etid
- Dallas, TX10 etid
- New York City, NY10 etid
- Myrtle Beach, SC9 etid
- Edison, NJ9 etid
- Baltimore, MD8 etid
- Syracuse, NY8 etid
- Nashville, TN8 etid
- Houston, TX7 etid
- Indianapolis, IN7 etid
- Philadelphia, PA7 etid
- Birmingham, AL7 etid
Lòt etid nan Lancaster
- Kansè Poumon ki pa ti selil7 etid
- Maladi kadyovaskilè5 etid
- Ensifizyans kadyak5 etid
- Kansè nan tete4 etid
- Kansè pwostat4 etid
- Kansè Metastatik4 etid
- Kansè poumon3 etid
- Amblyopi3 etid
- Maladi kè3 etid
- Kansè vejik3 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.